Respicardia, a leader in innovative technologies, was founded in 2006 and acquired by ZOLL in 2021. They specialize in addressing the unmet needs of individuals with Central Sleep Apnea (CSA), a serious condition that disrupts breathing during sleep. Their breakthrough implantable system, the remed System, restores a more normal breathing pattern and improves the quality of life and overall health of patients with CSA.
The remed System, FDA approved in 2017, is designed to treat moderate to severe CSA in adults by stimulating the respiratory muscles. It is indicated for patients who have been evaluated by a doctor and deemed suitable candidates. The system is MR Conditional, but conditions apply, and precautions must be taken to ensure safety. With a focus on patient well-being, Respicardia aims to provide effective treatment options for individuals suffering from CSA.
Generated from the website